Table 2.

Urine parameters in rats treated with lithium and/or parecoxib before, during, and after dDAVP injection.

BaselineCVCPLVLP
Diet intake (g/100 g per 24 h)16.5 ± 0.216.1 ± 0.311.6 ± 0.8*12.2 ± 1.0*
Feces excretion (g/100 g per 24 h)9.710.96.5*4.7*
Water intake (mL/100 g per 24 h)25.224.962.9*54.2*
Urine flow (mL/100 g per 24 h)10942.8*35.4*
Urinary sodium excretion (mmol/100 g per 24 h)0.76 ± 0.040.76 ± 0.041.08 ± 0.05*1.02 ± 0.05*
Urine PGE2 (ng/100 g per 24 h)31.9 ± 4.279.7 ± 29.226.7 ± 3.025.2 ± 2.5
dDAVP + 4 h
Urine flow (mL/100 g per 24 h)4.34.719.1*9
Urinary sodium excretion (mmol/100 g per 24 h)0.62 ± 0.060.54 ± 0.041.01 ± 0.210.28 ± 0.05#
dDAVP + 6 h
Urine flow (mL/100 g per 24 h)5.65.731.4*38.8*
Urinary sodium excretion (mmol/100 g per 24 h)1.33 ± 0.101.31 ± 0.090.94 ± 0.111.22 ± 0.18
  • Data have been analyzed with two‐way ANOVA followed by Bonferroni's multiple comparisons test. Data are presented as means ± SEM. When no standard error is shown data have been log transformed and the geometric mean is shown. Data that did not achieve normal distribution were analyzed with the nonparametric Kruskal–Wallis test followed by Dunn's multiple comparisons test.

  • * P < 0.05 compared to the CV and CP groups.

  • # P < 0.05 LP versus LV. N = 10 unless otherwise stated.